Legend Biotech Stock Rating Reiterated by H.C. Wainwright

H.C. Wainwright has reiterated its stock rating for Legend Biotech, noting new durability data. The firm emphasizes the importance of this data in assessing the company's long-term value. This affirmation comes as the company seeks to improve its market presence with new developments. For investors, this re-rating suggests a continued confidence in Legend Biotech's prospects, which may influence trading behavior.

Informational only, not financial advice. Content is AI-generated and may contain errors. How this works.